Detail of the clinical trial

Title of the trial A phase 3, multi-center, randomised, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid) as maintenance therapy for patients with b-cell chronic lymphocytic leukemia following second-line therapy (the continuum trial)
EudraCT number 2007-001626-27
Protocol number CC-5013-CLL-002
Sponsor Celgene Corporation, USA
Indications Hemato-oncology
Diagnosis B-cell chronic lymphocytic leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2008
Date of approval by Institute (SÚKL) 11.03.2009
Date of approval by EC 10.06.2009
Date of initiation CT in ČR 27.10.2009
Date of ending CT in ČR
Notice
Sites FN KV, Šrobárova, Praha 10 (discontinued)
Hematologie, Komplexní onkologické centrum Nový Jičín, Máchova
Hematoonkologické oddělení, FN Plzeň
Interní hematoonkologická klinika, FN Brno
1. interní klinika - klinika hematologie, 1. LF a VFN v Praze (discontinued)
2. interní klinika, odd. klinické hematologie, FN Hradec Králové (discontinued)

‹‹ Back to list